Central nervous system involvement in diffuse large B-cell lymphoma

   Introduction. Current approaches used to predict the recurrence of diffuse large B-cell lymphoma (DLBCL) with involvement of the central nervous system (CNS) need to be improved. Data from national studies on the incidence and clinical and laboratory characteristics of primary CNS DLBCL and secondary CNS involvement in systemic DLBCL are fragmentary and do not allow us to assess the overall picture.
   Aim. An assessment on the territory of the Siberian metropolis of data on the incidence and clinical and laboratory characteristics of DLBCL patients with primary CNS lymphoma (PCNSL) and secondary CNS involvement, as well as validation of the CNS-International Prognostic Index (CNS-IPI) on this sample.
   Materials and methods. The study group consisted of 47 patients with PCNSL and 35 with secondary CNS involvement in systemic DLBCL, the comparison group consisted of 202 patients with DLBCL without CNS involvement.
   Results. All patients with secondary CNS involvement in DLBCL belonged to the medium and high risk groups (p = 0.007) according to the CNS-IPI, which confi rms its prognostic value. The risk factors for secondary CNS involvement in DLBCL were ECOG performance status ≥ 2, HIV infection, age over 60 years, a history of chronic kidney disease, ≥ 2 extranodal sites, and high expression of Ki-67 (> 75 % positive tumor cells), non-GCB subtype of lymphoma, and presence of anemia. When assessing the characteristics of the clinical course of the disease, a number of peculiarities of the primary and secondary CNS involvement in DLBCL were identifi ed. In particular, in terms of overall survival, the PCNSL group had a more favorable prognosis (p = 0.051).
   Conclusion. The results of the study confi rm the importance of the CNS-IPI as a tool of a hematologist to determine the group of patients needing prevention of recurrence of DLBCL in the CNS. New data on a higher incidence of chronic kidney disease, arterial hypertension and thyroid disorders in the group of patients with PCNSL require further study.

1. Komratova K. A., Abugova Yu. G., Ozerov S. S. et al. Primary diffuse large B-cell lymphoma of the central nervous system (case report and literature review). Oncohematology. 2017; 12 (1): 10-16. DOI: 10.17650/1818-8346-2017-12-1-10-16. (In Russ.)

2. Haldorsen I. S., Espeland A., Larsson E.-M. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging // Am. J. Neuroradiol. 2011; 32 (6): 984-992. DOI: 10.3174/ajnr.A2171.

3. Tamma R., Ingravallo G., Albano F. et al. STAT-3 RNA-scope determination in human diff use large B-cell lymphoma // Transl. Oncol. 2019; 12 (3): 545-549. DOI: 10.1016/j.tranon.2018.12.008.

4. El-Galaly T. С., Villa D., Michaelsen T. Y. et al. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: Аn international multicenter study of 1532 patients treated with chemoim-munotherapy // Eur. J. Cancer. 2017; 75: 195-203. DOI: 10.1016/j.ejca.2016.12.029.

5. McMillan A., Ardeshna K. M., Cwynarski K. et al. Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology // Br. J. Haematol. 2013; 163 (2): 168-181. DOI: 10.1111/bjh.12509.

6. Wudhikarn K., Bunworasate U., Julamanee J. et al. Secondary central nervous system relapse in diff use large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry // Ann. Hematol. 2017; 96 (1): 57–64. DOI: 10.1007/s00277-016-2848-y.

7. Minenko S. V., Larina Yu. V., Ptushkin V. V. et al. Treatment of central nervous system lymphoma – literature review and own experiences. Oncohematology. 2011; 6 (3): 50-56. (In Russ.)

8. Magomedova A. U., Misyurina A. E., Mangasarova J. K. et al. CNS involvement and the feasibility of intratecal chemotherapy administration in patients with a nodal form of diffuse large B-cell lymphoma not otherwise specified. Data of prospective study. Therapeutic Archive. 2019; 91 (7): 35-40. DOI: 10.26442/00403660.2019.07.000323. (In Russ.)

9. Gubkin A., Zvonkov E., Kremenetskaya A. et al. Primary central nervous system lymphomas. Clinical Oncohematology. 2008; 1 (4): 323-332. (In Russ.)

10. Ilyaev N. P., Maksakova O. A., Zaytsev O. S. et al. Primary cerebral lymphoma. Mental disorders after biopsy (case report). The Russian Archives of Internal Medicine. 2019; 9 (6): 467-474. DOI: 10.20514/2226-6704-2019-9-6-467-474. (In Russ.)

11. Angeli E., Nguyen T. T., Janin A., Bousquet G. How to make anticancer drugs cross the blood-brain barrier to treat brain metastases // Int. J. Mol. Sci. 2020; 21 (1): 22. DOI: 10.3390/ijms21010022.

12. Ma’koseh M., Tamimi F., Abufara A. et al. Impact of central nervous system international prognostic index on the treatment of diff use large B cell lymphoma // Cureus. 2021; 13 (8): e16802. DOI: 10.7759/cureus.16802.

13. Klanova M., Sehn L. H., Bence-Bruckler I. et al. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL // Blood. 2019; 133 (9): 919-926. DOI: 10.1182/blood-2018-07-862862.

14. Ollila T. A., Kurt H., Waroich J. et al. Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma // Blood. 2021; 137 (8): 1120-1124. DOI: 10.1182/blood.2020007236.

15. Grimm K. E., O’Malley D. P. Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues // Ann. Diagn. Pathol. 2019; 38: 6-10. DOI: 10.1016/j.anndiagpath.2018.09.014.

16. Hans C. P., Weisenburger D. D., Greiner T. C. et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray // Blood. 2004; 103 (1): 275-282. DOI: 10.1182/blood-2003-05-1545.

17. Fursova L. A., Naumenko D. V. Thalamic infarcts in the system of artery of Percheron: clinical picture and diagnosis. International Neurological Journal. 2013; 1 (55): 25-33. (In Russ.)

18. Babicheva L. G. Extranodal non-Hodgkin’s lymphomas of the central nervous system, the testis and the pancreas. Journal of Modern Oncology. 2015; 17(5): 7-21. (In Russ.)

19. Peñalver F.-J., Sancho J.-M., de la Fuente A. et al. Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO) // Haematologica. 2017; 102 (2): 235-245. DOI: 10.3324/haematol.2016.149120.

20. Yudina T. V., Novikov Yu. V. Changes in the permeability of histo-hematic barriers under the infl uence of chemical environmental factors. Hygiene and Sanitation. 1971; 11. URL: https://cyberleninka.ru/article/n/izmenenie-pronitsaemosti-gisto-gematicheskih-barierov-pod-vliyaniem-himicheskih-faktorov-vneshney-sredy?ysclid=lbyqv9nrvj420539182 (accessed 07. 09. 2022). (In Russ.)

21. Gareev I. F., Beylerli O. A., Pavlov V. N. et al. Nanoparticles: a new approach to the diagnosis and treatment of cerebral glial tumours. Creative Surgery and Oncology. 2019; 9 (1): 66-74. DOI: 10.24060/2076-3093-2019-9-1-66-74. (In Russ.)

22. Skvortsova V. I. Arterial hypertension and cerebrovascular disorders. Systemic Hypertension. 2005; 2 (2): 3-10. (In Russ.)

23. Rzhevskaya O. N., Moiseeva A. Yu., Esaulenko A. N., Pinchuk A. V., Alidzhanova Kh. G. Chronic kidney disease as a risk factor for acute stroke. The Russian Journal of Transplantation. 2021; 13 (4): 382-397. (In Russ.)

24. Bernal J. The signifi cance of thyroid hormone transporters in the brain // Endocrinology. 2005; 146 (4): 1698-1700. DOI: 10.23873/2074-0506-2021-13-4-382-397.

25. Johanson C. E., Stopa E. G., McMillan P. N. The blood-cerebrospinal fluid barrier: structure and functional signifi cance // Methods Mol. Biol. 2011; 686: 101–31.